Compare $GTBP vs $KPTI | Chartloom

Compare

$GTBP vs $KPTI

GT Biopharma Inc · Karyopharm Therapeutics Inc

GTBP

GT Biopharma Inc

KPTI

Karyopharm Therapeutics Inc

Compare $GTBP vs $KPTI

Comparing GT Biopharma Inc and Karyopharm Therapeutics Inc

GTBPGT Biopharma Inc

KPTIKaryopharm Therapeutics Inc

GTBPGT Biopharma Inc

Market cap

$296M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-67.3%

52W performance

-75.3%

FCF yield

-4.9%

KPTIKaryopharm Therapeutics Inc

Market cap

$14M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

0.10x

Rev growth (TTM)

6.8%

YTD performance

-91.6%

52W performance

-89.7%

FCF yield

-476.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

GTBP

KPTI

Detailed metrics comparison

GTBP

GT Biopharma Inc

KPTI

Karyopharm Therapeutics Inc

Market Cap

GTBP$296M

KPTI$14M

Enterprise Value

GTBP$291M

KPTI$281M

Price

GTBP$6.68

KPTI$0.61

P/E Ratio

GTBPN/A

KPTIN/A

P/S Ratio

GTBP174.71x

KPTI0.09x

EV/Sales

GTBP95.98x

KPTI1.92x

EV/EBITDA

GTBP0.00x

KPTI0.00x

P/B Ratio

GTBP3.08x

KPTI0.36x

P/FCF Ratio

GTBPN/A

KPTIN/A

EV/FCF

GTBP-20.19x

KPTI-4.30x

PEG Ratio

GTBPN/A

KPTIN/A

Forward P/E (NTM)

GTBPN/A

KPTIN/A

Forward P/S (NTM)

GTBPN/A

KPTI0.10x

Revenue (TTM)

GTBP$0

KPTI$147M

Revenue Growth (YoY)

GTBPN/A

KPTI6.8%

Forward Rev Growth

GTBP216.5%

KPTI27.7%

Gross Margin (TTM)

GTBP36.5%

KPTI95.9%

Operating Margin (TTM)

GTBP0.0%

KPTI0.0%

EBITDA Margin (TTM)

GTBP0.0%

KPTI-56.1%

Net Margin (TTM)

GTBP0.0%

KPTI-153.3%

FCF Margin (TTM)

GTBPN/A

KPTI-44.6%

Net Income (TTM)

GTBP$-33M

KPTI$-225M

FCF (TTM)

GTBP$-14M

KPTI$-65M

EPS (TTM)

GTBP-$21.10

KPTI-$7.77

ROE (TTM)

GTBP-44308.0%

KPTI-18243.0%

ROA (TTM)

GTBP-31311.0%

KPTI-20094.0%

ROIC (TTM)

GTBP-44308.0%

KPTI-6632.0%

Cash

GTBP$5M

KPTI$55M

Debt

GTBP$0

KPTI$322M

Net Cash/Debt

GTBP$5M

KPTI$-267M

Current Ratio (TTM)

GTBP2.61x

KPTI0.79x

Quick Ratio (TTM)

GTBP2.51x

KPTI0.71x

Debt/Equity (TTM)

GTBP0.00x

KPTI3.78x

Debt/Assets (TTM)

GTBP0.0%

KPTI0.0%

Interest Coverage (TTM)

GTBPN/A

KPTIN/A

Net Debt/EBITDA (TTM)

GTBP0.00x

KPTI0.00x

Beta

GTBP0.81

KPTI1.14

52W Performance

GTBP-75.3%

KPTI-89.7%

YTD Performance

GTBP-67.3%

KPTI-91.6%

% from 52W High

GTBP-76.8%

KPTI-94.5%

% from 52W Low

GTBP36.0%

KPTI7.1%

Asset Turnover (TTM)

GTBP0.08x

KPTI1.31x

FCF Yield (TTM)

GTBP-4.9%

KPTI-476.7%

Earnings Yield (TTM)

GTBP-11.1%

KPTI-1639.3%

Dividend Yield (TTM)

GTBPN/A

KPTIN/A

Rule of 40

GTBP0.0

KPTI-37.8

EV/GP/RG

GTBPN/A

KPTI0.07

Ticker research

View GTBP research View KPTI research

Metric	GTBP GT Biopharma Inc	KPTI Karyopharm Therapeutics Inc
Market & Valuation
Market Cap	$296M	$14M
Enterprise Value	$291M	$281M
Price	$6.68	$0.61
P/E Ratio	N/A	N/A
P/S Ratio	174.71x	0.09x
EV/Sales	95.98x	1.92x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.08x	0.36x
P/FCF Ratio	N/A	N/A
EV/FCF	-20.19x	-4.30x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.10x
Revenue & Growth
Revenue (TTM)	$0	$147M
Revenue Growth (YoY)	N/A	6.8%
Forward Rev Growth	216.5%	27.7%
Profitability
Gross Margin (TTM)	36.5%	95.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-56.1%
Net Margin (TTM)	0.0%	-153.3%
FCF Margin (TTM)	N/A	-44.6%
Net Income (TTM)	$-33M	$-225M
FCF (TTM)	$-14M	$-65M
EPS (TTM)	-$21.10	-$7.77
ROE (TTM)	-44308.0%	-18243.0%
ROA (TTM)	-31311.0%	-20094.0%
ROIC (TTM)	-44308.0%	-6632.0%
Financial Health
Cash	$5M	$55M
Debt	$0	$322M
Net Cash/Debt	$5M	$-267M
Current Ratio (TTM)	2.61x	0.79x
Quick Ratio (TTM)	2.51x	0.71x
Debt/Equity (TTM)	0.00x	3.78x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.81	1.14
52W Performance	-75.3%	-89.7%
YTD Performance	-67.3%	-91.6%
% from 52W High	-76.8%	-94.5%
% from 52W Low	36.0%	7.1%
Efficiency & Yields
Asset Turnover (TTM)	0.08x	1.31x
FCF Yield (TTM)	-4.9%	-476.7%
Earnings Yield (TTM)	-11.1%	-1639.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-37.8
EV/GP/RG	N/A	0.07
Ticker research	View GTBP research	View KPTI research

Valuation

P/S Ratio

KPTI

0.09x

GTBP

174.71x

EV/FCF

GTBP

-20.19x

KPTI

-4.30x

Growth & revenue

Revenue Growth TTM

KPTI

6.8%

Forward Revenue Growth

GTBP

216.5%

KPTI

27.7%

Profitability & performance

Gross Margin

KPTI

95.9%

GTBP

36.5%

ROE

KPTI

-18243.0%

GTBP

-44308.0%

FCF Yield %

GTBP

-4.9%

KPTI

-476.7%

52-Week Performance

GTBP

-75.3%

KPTI

-89.7%

Detailed metrics comparison

GTBP

GT Biopharma Inc

KPTI

Karyopharm Therapeutics Inc

Market Cap

GTBP$296M

KPTI$14M

Enterprise Value

GTBP$291M

KPTI$281M

Price

GTBP$6.68

KPTI$0.61

P/E Ratio

GTBPN/A

KPTIN/A

P/S Ratio

GTBP174.71x

KPTI0.09x

EV/Sales

GTBP95.98x

KPTI1.92x

EV/EBITDA

GTBP0.00x

KPTI0.00x

P/B Ratio

GTBP3.08x

KPTI0.36x

P/FCF Ratio

GTBPN/A

KPTIN/A

EV/FCF

GTBP-20.19x

KPTI-4.30x

PEG Ratio

GTBPN/A

KPTIN/A

Forward P/E (NTM)

GTBPN/A

KPTIN/A

Forward P/S (NTM)

GTBPN/A

KPTI0.10x

Revenue (TTM)

GTBP$0

KPTI$147M

Revenue Growth (YoY)

GTBPN/A

KPTI6.8%

Forward Rev Growth

GTBP216.5%

KPTI27.7%

Gross Margin (TTM)

GTBP36.5%

KPTI95.9%

Operating Margin (TTM)

GTBP0.0%

KPTI0.0%

EBITDA Margin (TTM)

GTBP0.0%

KPTI-56.1%

Net Margin (TTM)

GTBP0.0%

KPTI-153.3%

FCF Margin (TTM)

GTBPN/A

KPTI-44.6%

Net Income (TTM)

GTBP$-33M

KPTI$-225M

FCF (TTM)

GTBP$-14M

KPTI$-65M

EPS (TTM)

GTBP-$21.10

KPTI-$7.77

ROE (TTM)

GTBP-44308.0%

KPTI-18243.0%

ROA (TTM)

GTBP-31311.0%

KPTI-20094.0%

ROIC (TTM)

GTBP-44308.0%

KPTI-6632.0%

Cash

GTBP$5M

KPTI$55M

Debt

GTBP$0

KPTI$322M

Net Cash/Debt

GTBP$5M

KPTI$-267M

Current Ratio (TTM)

GTBP2.61x

KPTI0.79x

Quick Ratio (TTM)

GTBP2.51x

KPTI0.71x

Debt/Equity (TTM)

GTBP0.00x

KPTI3.78x

Debt/Assets (TTM)

GTBP0.0%

KPTI0.0%

Interest Coverage (TTM)

GTBPN/A

KPTIN/A

Net Debt/EBITDA (TTM)

GTBP0.00x

KPTI0.00x

Beta

GTBP0.81

KPTI1.14

52W Performance

GTBP-75.3%

KPTI-89.7%

YTD Performance

GTBP-67.3%

KPTI-91.6%

% from 52W High

GTBP-76.8%

KPTI-94.5%

% from 52W Low

GTBP36.0%

KPTI7.1%

Asset Turnover (TTM)

GTBP0.08x

KPTI1.31x

FCF Yield (TTM)

GTBP-4.9%

KPTI-476.7%

Earnings Yield (TTM)

GTBP-11.1%

KPTI-1639.3%

Dividend Yield (TTM)

GTBPN/A

KPTIN/A

Rule of 40

GTBP0.0

KPTI-37.8

EV/GP/RG

GTBPN/A

KPTI0.07

Ticker research

View GTBP research View KPTI research

Metric	GTBP GT Biopharma Inc	KPTI Karyopharm Therapeutics Inc
Market & Valuation
Market Cap	$296M	$14M
Enterprise Value	$291M	$281M
Price	$6.68	$0.61
P/E Ratio	N/A	N/A
P/S Ratio	174.71x	0.09x
EV/Sales	95.98x	1.92x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.08x	0.36x
P/FCF Ratio	N/A	N/A
EV/FCF	-20.19x	-4.30x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.10x
Revenue & Growth
Revenue (TTM)	$0	$147M
Revenue Growth (YoY)	N/A	6.8%
Forward Rev Growth	216.5%	27.7%
Profitability
Gross Margin (TTM)	36.5%	95.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-56.1%
Net Margin (TTM)	0.0%	-153.3%
FCF Margin (TTM)	N/A	-44.6%
Net Income (TTM)	$-33M	$-225M
FCF (TTM)	$-14M	$-65M
EPS (TTM)	-$21.10	-$7.77
ROE (TTM)	-44308.0%	-18243.0%
ROA (TTM)	-31311.0%	-20094.0%
ROIC (TTM)	-44308.0%	-6632.0%
Financial Health
Cash	$5M	$55M
Debt	$0	$322M
Net Cash/Debt	$5M	$-267M
Current Ratio (TTM)	2.61x	0.79x
Quick Ratio (TTM)	2.51x	0.71x
Debt/Equity (TTM)	0.00x	3.78x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.81	1.14
52W Performance	-75.3%	-89.7%
YTD Performance	-67.3%	-91.6%
% from 52W High	-76.8%	-94.5%
% from 52W Low	36.0%	7.1%
Efficiency & Yields
Asset Turnover (TTM)	0.08x	1.31x
FCF Yield (TTM)	-4.9%	-476.7%
Earnings Yield (TTM)	-11.1%	-1639.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-37.8
EV/GP/RG	N/A	0.07
Ticker research	View GTBP research	View KPTI research